John C. Kath
Los Alamos National Laboratory(US)Claremont Graduate University(US)Pfizer (United States)(US)Claremont Institute(US)Université Bourgogne Franche-Comté(FR)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer, Monoclonal and Polyclonal Antibodies Research, Advanced Synthetic Organic Chemistry, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
- → Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor(2007)482 cited
- → Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271(2008)380 cited
- → Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes(2017)363 cited
- → A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors(2014)359 cited
- → Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance